Autor: |
Swain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K., Keane, C. |
Předmět: |
|
Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p278-279, 2p |
Abstrakt: |
B Conclusions: b Key differences in the TME are evident in DLBCL across treatment timepoints with reduced T cell infiltration and function at relapse demonstrated by immune gene expression and spatial transcriptome analysis. B Introduction: b Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) continue to have poor outcomes despite introduction of innovative immune based therapies. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|